The Narrow Gate

In 2013, the U.S. Supreme Court ruled that DNA occurring in nature could not be patented.

However, they noted that DNA processed in the laboratory could be patented. Specifically, a type known as complementary DNA (cDNA), a synthetic product derived from a molecule that serves as instructions for making proteins, or mRNA. It is no coincidence that this new mRNA technology is designed to perform this function.

In other words, there is now a patented synthetic cDNA floating irreversibly within an incalculable number of people. cDNA owned by corporations, which gives them grounds to claim ownership wherever their genetic therapeutic property exists. This puts governments and corporations in a potential position to justify coercing those who own their legitimate property.

Those who make these injections of mRNA literally become the property of the corporation.